Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have received a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $60.22.

A number of research analysts have commented on CLDX shares. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Finally, UBS Group assumed coverage on Celldex Therapeutics in a research note on Thursday. They set a “buy” rating and a $44.00 price objective for the company.

Celldex Therapeutics Stock Performance

Shares of CLDX stock opened at $22.70 on Friday. The firm has a fifty day moving average of $24.70 and a 200-day moving average of $29.79. The stock has a market cap of $1.51 billion, a price-to-earnings ratio of -8.83 and a beta of 1.60. Celldex Therapeutics has a 52-week low of $20.91 and a 52-week high of $53.18.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC raised its stake in shares of Celldex Therapeutics by 215.7% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 878 shares during the last quarter. KBC Group NV raised its position in Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 495 shares during the last quarter. Headlands Technologies LLC acquired a new position in Celldex Therapeutics during the 4th quarter worth $81,000. AlphaQuest LLC boosted its position in Celldex Therapeutics by 171.0% in the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 2,705 shares during the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Celldex Therapeutics in the 4th quarter valued at $121,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.